Idebenone Protects Photoreceptors Impaired by Oxidative Phosphorylation Disorder in Retinal Detachment

Area of Science:

• Cellular Biology
• Metabolic pathways
• Ophthalmology

Background:

• Oxidative phosphorylation (OXPHOS) is crucial for cellular energy production.
• Dysfunction in OXPHOS is implicated in ischemic diseases.
• Retinal detachment (RD) involves complex pathological changes, with limited research on metabolic alterations.

Purpose of the Study:

• To investigate metabolic changes, specifically OXPHOS, in retinal cells following RD.
• To explore the therapeutic potential of idebenone in addressing OXPHOS disorders in RD.

Main Methods:

• Single-cell RNA sequencing (scRNA-seq) analyzed human retinal cells post-RD.
• Animal models (mice) were used to study OXPHOS activity and the effects of idebenone.
• Idebenone, a CoQ10 analog, was administered to assess its impact on RD.

Main Results:

• ScRNA-seq identified abnormal energy metabolism and OXPHOS pathways in retinal cells after RD.
• RD led to increased reactive oxygen species (ROS) early and decreased adenosine triphosphate (ATP) synthesis later.
• Idebenone treatment reduced ROS, enhanced ATP synthesis, and preserved mitochondrial morphology.

Conclusions:

• OXPHOS disorder is a key factor in photoreceptor degeneration post-RD.
• Improving OXPHOS function offers a potential therapeutic strategy for RD.
• Idebenone demonstrates promise in mitigating RD-associated cellular damage.